Safety rules for drugs using during pregnancy and lactation Review article
Article Sidebar
Published:
Jun 30, 2021
Keywords:
pregnancy, pharmacotherapy, classification, lactation, infant, fetus
Main Article Content
Abstract
The use of drugs during pregnancy is often very complicated and causes many problems and doubts. Appropriate experience and medical knowledge as well as awareness of current scientific reports allow to assess the benefit-risk ratio and the effect of the drug on the developing fetus, the course of pregnancy and delivery. The choice of a drug should take into account the current health situation of the woman, pharmacokinetics of the drug and the ability to cross the placenta, and fetal toxicity. Available pregnancy classifications and registers can be helpful.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Tinker SC, Broussard CS, Frey MT et al. Prevalence of prescription medication use among non-pregnant women of childbearing age and pregnant women in the United States: NHANES, 1999-2006. Matern Child Health J. 2015; 19(5): 1097-106.
2. Mitchell AA, Gilboa SM, Werler MM et al; National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011; 205(1): 51.e1-8.
3. Pregnancy labeling. FDA Drug Bull. 1979; 9(4): 23-4.
4. Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products – Content and Format Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) July 2020 Labeling Revision 1.
5. Caritis SN, Venkataramanan R. Obstetrical, fetal, and lactation pharmacology – a crisis that can no longer be ignored. Am J Obstet Gynecol. 2021; 225(1): 10-20.
6. Committee for Medicinal Products for Human Use (CHMP). Guideline on risk assessment of Medicinal Products on Human Reproduction and Lactation: from data to labeling, 24.07.2008.
7. Wollman SC, Alhassoon OM, Hall MG et al. Gray matter abnormalities in opioid-dependent patients: A neuroimaging meta-analysis. Am J Drug Alcohol Abuse. 2017; 43(5): 505-17.
8. Monnelly VJ, Hamilton R, Chappell FM et al. Childhood neurodevelopment after prescription of maintenance methadone for opioid dependency in pregnancy: a systematic review and meta-analysis. Dev Med Child Neurol. 2019; 61(7): 750-60.
9. Soma-Pillay P, Nelson-Piercy C, Tolppanen H et al. Physiological changes in pregnancy. Cardiovasc J Afr. 2016; 27(2): 89-94.
10. Hebert MF, Ma X, Naraharisetti SB et al; Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther. 2009; 85(6): 607-14.
11. Bastian JR, Chen H, Zhang H et al. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. Am J Obstet Gynecol. 2017; 216(1): 64.e1-64.e7.
12. Pillai VC, Han K, Beigi RH et al. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. Br J Clin Pharmacol. 2015; 80(5): 1042-50.
13. Wesley BD, Sewell CA, Chang CY et al. Prescription medications for use in pregnancy – perspective from the US Food and Drug Administration. Am J Obstet Gynecol. 2021; 225(1): 21-32.
2. Mitchell AA, Gilboa SM, Werler MM et al; National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011; 205(1): 51.e1-8.
3. Pregnancy labeling. FDA Drug Bull. 1979; 9(4): 23-4.
4. Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products – Content and Format Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) July 2020 Labeling Revision 1.
5. Caritis SN, Venkataramanan R. Obstetrical, fetal, and lactation pharmacology – a crisis that can no longer be ignored. Am J Obstet Gynecol. 2021; 225(1): 10-20.
6. Committee for Medicinal Products for Human Use (CHMP). Guideline on risk assessment of Medicinal Products on Human Reproduction and Lactation: from data to labeling, 24.07.2008.
7. Wollman SC, Alhassoon OM, Hall MG et al. Gray matter abnormalities in opioid-dependent patients: A neuroimaging meta-analysis. Am J Drug Alcohol Abuse. 2017; 43(5): 505-17.
8. Monnelly VJ, Hamilton R, Chappell FM et al. Childhood neurodevelopment after prescription of maintenance methadone for opioid dependency in pregnancy: a systematic review and meta-analysis. Dev Med Child Neurol. 2019; 61(7): 750-60.
9. Soma-Pillay P, Nelson-Piercy C, Tolppanen H et al. Physiological changes in pregnancy. Cardiovasc J Afr. 2016; 27(2): 89-94.
10. Hebert MF, Ma X, Naraharisetti SB et al; Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther. 2009; 85(6): 607-14.
11. Bastian JR, Chen H, Zhang H et al. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. Am J Obstet Gynecol. 2017; 216(1): 64.e1-64.e7.
12. Pillai VC, Han K, Beigi RH et al. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. Br J Clin Pharmacol. 2015; 80(5): 1042-50.
13. Wesley BD, Sewell CA, Chang CY et al. Prescription medications for use in pregnancy – perspective from the US Food and Drug Administration. Am J Obstet Gynecol. 2021; 225(1): 21-32.